Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Rezvani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified hem-oncologist, specializing in stem cell transplantation and cellular therapy.
Education & Training
- Imperial CollegePh.D., Transplant Immunology, 2005
- University of London Faculty of MedicineClass of 1993
- University CollegeB.S., Neuroanatomy/Neuroscience, 1990
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2015 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Clinical Excellence Award Imperial College London, 2011
- Clinical Excellence award Hammersmith Hospital, London, 2010
- R. Lee Clark Award in Clinical excellence MD Anderson Cancer center, 2008
- Join now to see all
Clinical Trials
- Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor Start of enrollment: 2009 Aug 01
- Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation Start of enrollment: 2011 Apr 01
- CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation Start of enrollment: 2011 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- The Impact of Isolated HLA-DQB1 Mismatch and Donor Age in Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide.Rohtesh S Mehta, Yosra M Aljawai, Partow Kebriaei, Amanda Olson, Betul Oran
Transplantation and Cellular Therapy. 2025-08-15 - Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis.Yosra M Aljawai, Jeremy Ramdial, Gabriela Rondon, Portia Smallbone, Partow Kebriaei
Blood Advances. 2025-08-12 - Comparative Outcomes of HCT with Post-Transplant Cyclophosphamide in Older Adults: The Impact of Donor Type.Yosra M Aljawai, Jeremy L Ramdial, Portia Smallbone, George Liwei Chen, Partow Kebriaei
Blood Advances. 2025-08-12
Journal Articles
- Use of CAR-Transduced NK Cells in CD19-Positive Lymphoid TumorsKatayoun Rezvani, MD, The New England Journal of Medicine
- Management Guidelines for Paediatric Patients Receiving Chimeric Antigen Receptor T Cell TherapyKris M Mahadeo, Julie C Fitzgerald, Marie E Steiner, Partow Kebriaei, Katayoun Rezvani, Ira M Cheifetz, John M Slopis, Paul L Martin, Sattva S Neelapu, Agne Tarasevici..., Nature
- A subset of virus-specific CD161(+) T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AMLAlsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, A..., Blood, 1/1/2017
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following AllotransplantationKatayoun Rezvani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell TransplantationKatayoun Rezvani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Next Generation CRISPR Gene-Edited and Off-the-Shelf Virus-Specific T-Cells for the Immunocompromised PatientKatayoun Rezvani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Cellular Therapy in Glioblastoma1/1/2018
- CAR-NK Cells: can they compete with CAR-T in immunooncologyBerlin, Germany - 1/1/2018
- CAR-T/Cellular Therapy -Clinical UpdateSalt Lake City, UT - 1/1/2018
- Join now to see all
Authored Content
- Use of CAR-Transduced NK Cells in CD19-Positive Lymphoid TumorsFebruary 2020
Press Mentions
- Engineered Immune Cells Elicit a Strong Immune Response Against Brain CancerAugust 15th, 2024
- Annual Meeting 2022: Natural Killer Cells and the Antitumor Immune ResponseJune 7th, 2022
- Promising Early Results with CAR-NK CellsFebruary 6th, 2020
- Join now to see all
Professional Memberships
- Member
- American Society Blood and Marrow TransplantationMember
- International Society Cell therapyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: